恒生港股通创新药指数通过在编制方案中剔除CXO，成为ETF跟踪的指数中首批"纯度"100%的创新药 指数，更加精准地反映我国创新药企的整体表现。目前，恒生创新药ETF（159316）是市场唯一跟踪该 指数的产品，可助力投资者精准布局创新药产业发展机遇。 昨日，恒瑞医药宣布与全球制药公司Glenmark达成独家许可协议，将其自主研发的HER2 ADC药物瑞康 曲妥珠单抗(1811)在除中、美、欧、日等核心市场外的全球权益授权给Glenmark，并收取1800万美元首 付款及最高10.93亿美元的潜在里程碑付款。 有分析认为，恒瑞医药HER2 ADC药物的海外授权交易证明中国创新药企已具备全球竞争力，此次交易 打破了近期创新药板块缺乏BD事件催化的平淡局面，加之即将到来的欧洲肿瘤内科学会及第四季度传 统BD交易高频期，市场对后续BD事件预期升温，有望开启新一轮创新药行情。 港股创新药板块午后维持红盘震荡，截至14:45，恒生港股通创新药指数上涨0.6%，云顶新耀涨超5%， 乐普生物-B涨超3%，康方生物、恒瑞医药等多股涨超1%，此前连续3日"吸金"的恒生创新药ETF （159316）盘中再获2100万份净申购。 ...

港股医药板块早盘冲高后下挫，午前再度回暖，截至午间收盘，中证港股通医药卫生综合指数上涨 0.5%，恒生港股通创新药指数上涨0.4%，中证创新药产业指数上涨0.2%，中证生物科技主题指数上涨 0.1%，沪深300医药卫生指数接近平收。 每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com | 液制品及其它人体生物科技 的公司股票组成。 | 0.1% | 63.9倍 84.4% | | --- | --- | --- | | 矢约ETF ONLY | | 512010 | | 跟踪沪深300医药卫生指数 | | | | | | .. / | | 该指数聚焦A股医药卫生行 | | | | 业龙头,由沪深300指数样 | 重逢年间收费 | 19 - 191 该指数自2007年 | | 本中属于医药卫生行业的公 | 该指数涨跌 | 新闻网 发布以来估值分位 | | 司股票组成,全面覆 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 0.4%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 0.1% [1] - The CSI Biotechnology Theme Index increased by 0.1%, and the CSI Innovative Drug Industry Index rose by 0.2% [1] - The CSI 300 Pharmaceutical and Health Index saw an increase of 0.4% [1] Group 2 - The Hang Seng Innovative Drug ETF (159316) experienced a net inflow of 580 million yuan last week, bringing its total size to 2.7 billion yuan, marking a historical high [1] - The rolling price-to-earnings ratio for the pharmaceutical and health industry is reported at 33.5 times, with a valuation percentile of 63.4% [4] - The liquid products and other human biotechnology sector have a rolling price-to-earnings ratio of 64.2 times, with a valuation percentile of 85.3% [4]

申万宏源证券指出，中国创新药板块目前具有"创新升级+盈利拐点+出海BD常态化"三重逻辑，这三重逻辑将持续支撑后续 行情，看好中国创新药板块长期的投资价值。 | | 恒生港股通 | 中证落股通 | 中证创新 | 中证牛物 | 沪深300 | | --- | --- | --- | --- | --- | --- | | | 创新药指数 | 医药卫生综 | 药产业指 | 科技主题 | 铁药卫生 | | | | 合指数 | 151 | 指数 | 指数 | | 本周涨跌幅 | -3.0% | -1. 7% | -1. 8% | -0. 7% | -1.2% | | 指数估值 | 滚动市盈率 63.0倍 | 滚动市盈率 31.1倍 | 滚动市盈率 57.9倍 | 滚动市盈率 63.7倍 | 滚动市盈率 33.6倍 | | 指数估值 分位 | 2023年7月 10日发布 | 48. 5% | 88. 8% | 84. 2% | 63.9% | | 跟踪该 | | 恒生创新药 港股通医药 | 创新药ETF | 生物科技 | 矢药ETF | | 指数的 ETF | ETE | ETF | 易方达 | ETF | (51201 ...

截至收盘，恒生港股通创新药指数下跌3.6%，中证港股通医药卫生综合指数下跌3.0%，中证创新药产业指数下跌0.5%，沪深300医药卫生指数下跌0.4%，中 证生物科技主题指数下跌0.2%，恒生创新药ETF（159316）全天获1.02亿份净申购。截至昨日，该产品连续5日获资金净流入，最新规模达26亿元、创历史 新高。 跟踪中证创新药产业指数 该指数聚焦A股创新药龙头, 由不超过50只主营业务涉 及创新药研发的公司股票 组成,汇聚A股创新药主力 车。 该指数自201 该指数 रु B 发布以来估值 该指数涨跌 滚可向盘率 -0.5% 58.4倍 90.1% 生物科技ETF(No.) 低碳 跟踪中证生物科技主题指数 该指数聚焦A股生物科技龙 头,由不超过50只业务涉 及基因诊断、生物制药、血 液制品及其它人体生物科技 的公司股票组成。 中信建投证券称，从中报业绩来看，创新药、CXO、生物制药等医药行业细分板块均迎来业绩修复，中国医药产业当前已具备全球竞争力，长期看好医药 行业走出全球性大公司。 该指数自20 该指数 �日 发布以来估值 该指数涨跌 滚动市盘率 33.6倍 63.9% -0.4% 注:"N0.1"标 ...

Market Performance - The market showed strong performance throughout the day, with major indices rebounding significantly, and both the ChiNext Index and Shenzhen Component Index reaching new highs for the year [1] - Over 4,200 stocks in the market experienced gains, indicating a broad-based rally [1] Index Movements - The broad-based indices almost all rose, with growth-style indices represented by the ChiNext and Sci-Tech Innovation boards leading the way, as the ChiNext 50 Index increased by over 6% and the ChiNext Index rose by over 5% [1] - The ChiNext ETF (159915) and Sci-Tech Innovation 50 ETF (588080) saw active trading [1] Sector Highlights - The CPO and PCB sectors were among the top gainers, driving the performance of indices related to communication equipment and 5G communication, which also saw significant increases [1] - Other sectors such as artificial intelligence and cloud computing also performed well, with notable gains [1] Investment Trends - According to招商证券, the short-term market adjustment is nearing its end, transitioning to a more sustained low-slope upward trend, with a focus on AI computing power, solid-state batteries, humanoid robots, and commercial aerospace/satellite internet in September [1]

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing growth in revenue and a significant reduction in losses, driven by technological breakthroughs, accelerated internationalization, and policy support [1]. Group 1: Market Performance - The Hang Seng Innovative Drug Index fell by 2.0%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 1.1% [1]. - The CSI Innovative Drug Industry Index and the CSI Biotechnology Theme Index saw declines of 0.6% and 0.5%, respectively [1]. - The Hang Seng Innovative Drug ETF (159316) recorded over 100 million net subscriptions throughout the day, marking four consecutive days of net inflow, with the latest scale reaching 2.5 billion yuan, a historical high [1]. Group 2: Industry Outlook - CITIC Construction Investment Securities forecasts that by the first half of 2025, revenue for Chinese innovative pharmaceutical companies will continue to grow, with losses significantly narrowing [1]. - The valuation of the innovative drug industry is expected to rise substantially, reflecting an enhancement in global competitiveness [1]. - The sector's accelerated development is attributed to three driving forces: technological breakthroughs, internationalization, and supportive policies [1].

Core Insights - The Hang Seng Hong Kong Stock Connect Innovation Drug Index increased by 7.1% this week, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index rose by 6.9% [1] - The CSI Innovation Drug Industry Index and the CSI Biotechnology Theme Index saw increases of 5.3% and 3.6%, respectively, with the CSI 300 Medical and Health Index up by 3.4% [1] - The Hang Seng Innovation Drug ETF (159316) experienced a net inflow of nearly 200 million yuan this week, bringing its total size to over 2 billion yuan, a record high [1] Index Performance - Weekly performance: - Hang Seng Innovation Drug Index: +7.1% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: +6.9% - CSI Innovation Drug Industry Index: +5.3% - CSI Biotechnology Theme Index: +3.6% - CSI 300 Medical and Health Index: +3.4% [3] - Year-to-date performance: - Hang Seng Innovation Drug Index: +116.2% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: +102.9% - CSI Innovation Drug Industry Index: +43.5% - CSI Biotechnology Theme Index: +31.2% - CSI 300 Medical and Health Index: +22.9% [7] Valuation Metrics - Current rolling P/E ratios: - Hang Seng Innovation Drug Index: 57.7x - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: 30.7x - CSI Innovation Drug Industry Index: 57.3x - CSI Biotechnology Theme Index: 62.3x - CSI 300 Medical and Health Index: 33.0x [3] - Valuation percentile as of July 2023: - Hang Seng Innovation Drug Index: 48.5% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: 88.1% - CSI Innovation Drug Industry Index: 82.1% - CSI Biotechnology Theme Index: 60.2% [3] ETF Overview - The Hang Seng Innovation Drug Index has one ETF tracking it, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index has four ETFs [5] - The CSI Innovation Drug Industry Index is tracked by seven ETFs, and the CSI Biotechnology Theme Index has four ETFs [5]

Core Insights - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 3.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rose by 2.7% [1] - The CSI Innovative Drug Industry Index and the CSI Biotechnology Theme Index both saw a 2.0% increase, and the CSI 300 Pharmaceutical and Health Index rose by 1.8% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of 6 million units in half a day, with a net inflow exceeding 1 billion yuan in the past month, bringing its total scale to over 2 billion yuan, a record high [1] Index Performance - The CSI Innovative Drug Industry Index consists of no more than 50 stocks primarily involved in innovative drug research and development, representing the leading companies in A-share innovative drugs [5] - The index has a rolling price-to-earnings ratio of 57.3 times and has appreciated by 88.1% since its inception [6] - The CSI Biotechnology Theme Index, which focuses on leading A-share biotechnology companies, also consists of no more than 50 stocks involved in gene diagnosis, biopharmaceuticals, and other human biotechnology sectors, with a rolling price-to-earnings ratio of 62.3 times and an appreciation of 82.1% since its inception [7] Sector Coverage - The CSI 300 Pharmaceutical and Health Index covers leading companies in the pharmaceutical and health industry, including segments such as chemical pharmaceuticals, medical services, and medical devices [8] - This index has a rolling price-to-earnings ratio of 33.0 times and has appreciated by 60.2% since its inception [9]

Group 1 - The Hong Kong stock market is experiencing an upward trend, with the innovative pharmaceutical sector showing strong performance, as evidenced by a 3.5% increase in the Hang Seng Innovative Drug Index and over 400 million yuan in trading volume for the Hang Seng Innovative Drug ETF (159316) [1] - Hengrui Medicine announced a significant overseas business development (BD) deal worth over 1 billion USD for its drug HRS-1893, with an upfront payment of 65 million USD, aimed at expanding its market reach and providing quality treatment options globally [1] - Guosen Securities highlighted that the innovative drug sector has performed well in the first half of the year, driven by successful BD collaborations, excellent clinical data, and supportive policies, indicating a rapid increase in the commercial value of newly launched products [1] Group 2 - The Hang Seng Innovative Drug Index has been adjusted to exclude contract research organizations (CROs), achieving a "purity" of 100% for innovative drug companies, which allows for a more accurate reflection of the overall performance of China's innovative pharmaceutical sector [2] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this newly adjusted index, providing investors with a precise opportunity to capitalize on the growth of the innovative drug industry [2]